Pulmatrix has announced that topline data from a Phase 1b study of its PUR1800 dry powder narrow spectrum kinase inhibitor in COPD patients showed that inhaled PUR1800 produced “low and consistent systemic exposure” with “no observed safety signals” In January 2020, when Pulmatrix announced a license agreement with the Lung Cancer Initiative at Johnson & Johnson involving its narrow spectrum kinase inhibitors, the company said that it would be due a $2 million payment on completion of the Phase 1b study of PUR1800 in COPD patients.
Newly hired Pulmatrix Chief Medical Officer Margaret Wasilewski said, “We are very encouraged by the safety and preliminary pharmacokinetic results in this study. We will continue to evaluate the complete datasets and expect to submit study results at a relevant medical conference later this year.”
Pulmatrix CEO Ted Raad commented, “This topline data, along with the results from chronic toxicology studies, support the continued development of PUR1800 for the treatment of AECOPD and other inflammatory respiratory disease. The Phase 1b results are an important step towards advancing PUR1800 into Phase 2 studies and we believe that PUR1800’s comprehensive data set will facilitate productive discussions with investors and potential partners.”
Read the Pulmatrix press release.
